Clin2
NCT07077668Possibly a fitNot yet recruiting

Study of RAG-17 for ALS with SOD1 gene changes

ALS (Amyotrophic Lateral Sclerosis)

Part of Brain & nervous system, Hormones & metabolism clinical trials.

This study tests an experimental treatment called RAG-17 for people with ALS who have a specific genetic change in the SOD1 gene. The goal is to see if it can slow down the disease and improve symptoms.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
10 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have been diagnosed with ALS (either familial or sporadic) and have a confirmed SOD1 gene mutation.
  • You have not received any vaccines in the last 28 days.
  • You do not have severe liver, kidney, or heart problems.
  • You are not pregnant, planning to become pregnant, or breastfeeding.
  • You do not have a history of alcohol or drug abuse.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07400393Not yet recruiting
ALS genetic screening study for new treatments

This study screens people with ALS to see if they might qualify for future gene-targeted treatments. It helps match you to trials that may be a good fit for your genetic type.

NCT07294144Recruiting· Phase 2
Tofersen for ALS without SOD1 or FUS mutations

This trial tests if tofersen, a drug that targets a protein linked to ALS, can help people who have ALS but do not have mutations in the SOD1 or FUS genes. It aims to slow disease progression in those diagnosed within the last 2 years.

Atlanta, Georgia
NCT06556394Recruiting· Phase 1
Testing RAG-17 for ALS with SOD1 gene mutation

This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.

Beijing
NCT06351592Recruiting· Phase 1/Phase 2
Study of ALN-SOD for ALS with SOD1 gene mutation

This trial tests an experimental drug called ALN-SOD for people with ALS caused by a specific genetic mutation in the SOD1 gene. The goal is to see if it is safe and can help slow the disease.

Concord, New South Wales
NCT07080801Not yet recruiting· Early Phase 1
New drug RAG-21 for ALS with FUS gene changes

This trial tests a new drug called RAG-21 in people with ALS who have a specific genetic change (FUS gene mutation). The goal is to see if it is safe and effective in slowing the disease.

NCT06849609Recruiting· Early Phase 1
Gene therapy VGN-R13 for ALS safety and tolerability

This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.

Wuhan, Hubei

Hear when a new ALS (Amyotrophic Lateral Sclerosis) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.